Novavax shares surged 16%, leading a biotech sector rally alongside Moderna's 11% gain and Merck's 3% rise. The spike occurred without any new company-specific announcements, driven by a broad sector-wide bid in vaccine and biotech stocks. Novavax's unique licensing model, relying on milestone payments from partners rather than direct sales, makes its stock more sensitive to market sentiment. Investors should watch for partner milestone news and biotech sector trends to gauge future movements, while managing risk due to the stock's volatility on sentiment alone.
Novavax leads with a 16.53% increase on Pluang, priced at USD 12.83 as of Oct 10, 2026 01:11 WIB, reflecting strong sector interest despite no new company news. Moderna also shows significant gains, up 11.84% at USD 220.32, while Merck rises 2.59% to USD 146.08. Pluang order activity reveals a majority buying trend for Novavax (59%) and Merck (60%), contrasting with Moderna's 71% selling activity, illustrating varied investor sentiment within the biotech rally.
Vaccine stocks surged after a Siberian plague scare, but health officials have since declared the risk low, causing Novavax shares to drop 2% after a prior 20% spike. Novavax's rally was driven by speculation of government vaccine purchases, but the ...
Novavax shares surged 22% following Sanofi's rollout of the Nuvaxovid COVID-19 vaccine for the fall season, giving Novavax a commercial boost through its licensing deal. Unlike Moderna and BioNTech, Novavax earns royalties from Sanofi's sales rather ...
